Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
8.51
Industry P/E
--
Debt to Equity
0.39
ROE
-3.78 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.86
CFO
$-192.01 Mln
EBITDA
$-251.78 Mln
Net Profit
$-258.63 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Organovo Holdings (ONVO)
| -63.58 | -35.99 | -56.38 | -84.77 | -61.91 | -52.28 | -46.63 |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Organovo Holdings (ONVO)
| -58.27 | -21.28 | -61.16 | -70.49 | 72.90 | -62.84 | -28.44 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.48 | 9,808.03 | 20.22 | 23.13 | |
| 282.28 | 8,956.09 | 22.08 | 58.42 | |
| 25.74 | 9,559.25 | -- | -28.77 | |
| 101.74 | 10,030.35 | 30.81 | 14.16 |
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the... fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California. Address: 11555 Sorrento Valley Road, San Diego, CA, United States, 92121 Read more
Company Secretary & Executive Chairman
Mr. Keith E. Murphy
Company Secretary & Executive Chairman
Mr. Keith E. Murphy
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Organovo Holdings Inc (ONVO) stood at $ 7 Mln as on 31-Dec-24
The share price of Organovo Holdings Inc (ONVO) is $2.01 (NASDAQ) as of 22-Apr-2025 16:00 EDT. Organovo Holdings Inc (ONVO) has given a return of -61.91% in the last 3 years.
Organovo Holdings Inc (ONVO) has a market capitalisation of $ 3 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Organovo Holdings Inc (ONVO) is 8.51 times as on 21-Apr-2025, a 278% premium to its peers’ median range of 2.25 times.
Since, TTM earnings of Organovo Holdings Inc (ONVO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Organovo Holdings Inc (ONVO) and enter the required number of quantities and click on buy to purchase the shares of Organovo Holdings Inc (ONVO).
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California. Address: 11555 Sorrento Valley Road, San Diego, CA, United States, 92121
The CEO & director of Mr. Keith E. Murphy. is Organovo Holdings Inc (ONVO), and CFO & Sr. VP is Mr. Keith E. Murphy.
There is no promoter pledging in Organovo Holdings Inc (ONVO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Organovo Holdings Inc. (ONVO) | Ratios |
|---|---|
|
Return on equity(%)
|
-352.55
|
|
Operating margin(%)
|
-10272.13
|
|
Net Margin(%)
|
-10151.64
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Organovo Holdings Inc (ONVO) was $0 Mln.
$0.26
(
